This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Guimarães, J Articles by Sá, M J Search for Related Content PubMed PubMed Citation Articles by Guimarães, J Articles by Sá, M J Social Bookmarking                         What's this?

Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis

Department of Neurology, Hospital S. João, Porto, Portugal

M J Cardoso

Laboratory of Microbiology and Serology, Hospital S. João, Porto, Portugal

M J Sá

Institute of Anatomy, Porto Medical School, Alameda Hernani Monteiro 4202-451, Porto, Portugal

Background The descriptions of early axonal damage in patients with multiple sclerosis (MS) prompted the search of body fluid markers. However, the studies addressing this issue in MS present conflicting results.

Aim To assess the levels of tau protein in patients with definite MS.

Patients and methods Cerebrospinal fluid (CSF) samples from 50 patients with definite diagnosis of MS (33 F, 17 M; mean age: 33.6 years) and from 19 age-matched individuals without organic neurological diseases (11 F, 8 M), entered this study. With regard to the clinical course, the MS patients were classified as follows: 32 relapsing-remitting (RR); two secondary progressive (SP), and four primary progressive (PP). Twelve patients had clinical isolated syndromes (CIS). The mean duration was 36.1 months (range: 15 days to 20 years). Tau protein was measured in the CSF by double antibody sandwich ELISA.

Results The median tau and the cut-off values of the controls were 104.9 and 175.3 pg/mL, respectively. We found that most MS patients presented normal values. In addition, the clinical features-course, duration, Expanded Disability Status Scale (EDSS) value, Poser index of progression, Multiple Sclerosis Severity Score-did not significantly influence the tau levels in the MS group.

Conclusion Our study showed similar CSF tau concentrations in MS patients with different clinical characteristics. This suggests that tau protein does not seem to be a useful routine clinical marker of axonal damage.

Key Words: axonal damage in MS • multiple sclerosis • tau protein

Multiple Sclerosis, Vol. 12, No. 3, 354-356 (2006)
DOI: 10.1191/1352458506ms1288sr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. E. Teunissen, E. Iacobaeus, M. Khademi, L. Brundin, N. Norgren, M.J.A. Koel-Simmelink, M. Schepens, F. Bouwman, H. A.M. Twaalfhoven, H. J. Blom, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis Neurology, April 14, 2009; 72(15): 1322 - 1329. [Abstract] [Full Text] [PDF]